Search 

Almac Discovery is a research driven drug discovery company operating within the Almac Group of companies dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS). Our business model is primarily to discover and develop novel First-in-Class drug candidates through to pre-clinical development, and then to seek pharmaceutical or biotech partners for clinical development and commercialisation. Key research themes are two-fold: a) Controlling protein homeostasis through targeting Deubiquitinase (DUB) enzymes, and, b) Generating novel protein drug conjugates (PDCs) utilising single chain antigen recognition domains linked to Almac’s proprietary linker:payload technology.

Curileum is a biotechnology company in London that focuses on
discovering and developing novel therapeutics to intervene early
in the development of severe GI diseases. With a dynamic team of
scientists committed to translating our science to game-changing
therapies, we have discovered and delivered two first-in-class
preclinical therapeutic candidates and a compelling novel drug
target.
ULI-015 a small molecule to reduce polyp formation and progression
to bowel cancer.
ATZ stem cell therapy to repair an incurable condition in Crohn’s
disease patients.
CSR-1 a soluble regulator in Crohn’s patients that drives chronic gut
inflammation.
Curileum is seeking co-development and licensing partners for its
two de-risked, first-in-class preclinical therapeutic candidates and a
collaboration partner to develop a small molecule antagonist to our
novel drug target driving chronic gut inflammation.
Learn more at curileum.com

Medherant develops patches for transdermal drug delivery using our proprietary TEPI-Patch® technology. Key advantages of the TEPI Patch® technology over current technologies include excellent adhesion that can be tailored for up to 7-days of drug delivery, whilst still being easy and painless to remove.  

The TEPI Patch® provides a better experience for the user as it does not leave a residue or dirty mark around the patch – referred to as ‘cold flow’. No organic solvents are involved in manufacture of this drug-in-adhesive system.

As well as developing our own products, some of which have already been successfully tested in clinical studies, Medherant is working with pharmaceutical companies to develop new products. We are seeking additional partners and can offer rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of drugs of interest.

The NIHR (National Institute for Health and Care Research) enables, funds and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.

The NIHR:

- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research

- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future

- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services

- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

Oppilotech develops first-in-class drugs. We believe that target selection is the most important decision we make in drug discovery – a selective high-quality molecule will never become a drug if it is modulating the wrong target. Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets. We undertake both the target selection and develop the drugs against the identified target. We initially focused our modelling efforts on E.coli identifying several first-in-class antibacterial drug targets and generated active chemical matter against them. The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (e.g. DNA Damage Response) and inflammation.

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.